NCT06592365 Clinical Study to Evaluate the Effects and Safety of Green Tea Extract on Blood Glucose Regulation
| NCT ID | NCT06592365 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Amorepacific Corporation |
| Condition | Blood Sugar |
| Study Type | INTERVENTIONAL |
| Enrollment | 84 participants |
| Start Date | 2022-08-08 |
| Primary Completion | 2024-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 84 participants in total. It began in 2022-08-08 with a primary completion date of 2024-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
This study was conducted to investigate the effects of green tea extracts on reducing blood glucose level
Eligibility Criteria
Inclusion Criteria: * Males and females aged between 19 to 64 years * BMI between 18.5 and 29.9kg/m² * fasting blood glucose between 100 and 139 mg/dL (Note: if some subjects with blood glucose range of 126 - 139 mg/dL, those who are taking or requre medication must be excluded to meet ethical standards.) * subjects who voluntarily decide to participate in this study and sign the informed consent form. Exclusion Criteria: * Individuals taking to obesity, dyslipidemia, or uncontrolled hypertension at the screening * Individuals diagnosed with diabetes and who have taken medications related to blood glucose * Individuals congenital enzyme deficiencies related to sugar metabolism. * with hypersensitivity to the test food or ingredients(e.g., green tea, caffeine). * Individuals ongoing treatment diseases significantly related glucose metabolism. * Individuals with a history of surgery significantly related to glucose metabolism within the last 6 months * diagnosed with gastrointestinal diseases, cardiovascular diseases, uncontrolled chronic medical conditions, thyroid disorders, or active malignant tumors requiring medication * Individuals with liver function impairment or acute or chronic hepatitis or liver cirrhosis * Individuals with renal disorder * Individuals with a weight change of 5 kg or more within the last 3 months.
Contact & Investigator
Jae-Heon Kang, MD, PhD
PRINCIPAL INVESTIGATOR
Kangbuk Samsung Hospital
Frequently Asked Questions
Who can join the NCT06592365 clinical trial?
This trial is open to participants of all sexes, aged 19 Years or older, up to 64 Years, studying Blood Sugar. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06592365 currently recruiting?
Yes, NCT06592365 is actively recruiting participants. Contact the research team at sohnjh@amorepacific.com for enrollment information.
Where is the NCT06592365 trial being conducted?
This trial is being conducted at Seoul, South Korea, Seoul, South Korea, Seoul, South Korea.
Who is sponsoring the NCT06592365 clinical trial?
NCT06592365 is sponsored by Amorepacific Corporation. The principal investigator is Jae-Heon Kang, MD, PhD at Kangbuk Samsung Hospital. The trial plans to enroll 84 participants.